Examine progress toward accelerated approval for an off-the-shelf dual-target CAR-T and its implications for global cell therapy adoption.
Key Takeaways
- Chinese biotech’s universal CAR-T therapy secures FDA’s three top expedited designations
- Has received both Regenerative Medicine Advanced Therapy (RMAT)
- It is also the first cell therapy developed in China to achieve all three designations